DOP20 Genetic of vitamin D as predictor of response to adalimumab in Crohn’s Disease
| Autor: | C. Tomasello, Lorenzo Bertani, Jessica Cusato, Gian Paolo Caviglia, Davide Giuseppe Ribaldone, Antonio D'Avolio, M. Mangia, S Dibetto, Marco Astegiano, Miriam Antonucci |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Crohn's disease Vitamin D-binding protein business.industry Gastroenterology Vitamin D3 24-Hydroxylase Single-nucleotide polymorphism General Medicine medicine.disease Inflammatory bowel disease Immune system Internal medicine Vitamin D and neurology medicine Adalimumab business medicine.drug |
| Zdroj: | Journal of Crohn's and Colitis. 15:S058-S061 |
| ISSN: | 1876-4479 1873-9946 |
| Popis: | Background Personalised medicine is the direction towards are converging many efforts of experts in inflammatory bowel diseases (IBDs). The advent of biological drugs, with anti-TNF as first category, have revolutionized the managements of these patients. Unfortunately, several unmet needs are present, like an efficacy in about two third of the patients, onset of side effects like infections, paradoxical IMIDs. Being able to treat with these drugs only patients who will respond would avoid losing time without disease improvement and possible side effects. Vitamin D is important for several biological functions, such as regulation of the immune response and modulation of expression of genes encoding enzymes and transporters involved in drug metabolism and transport. Vitamin D is activated by cytochrome (CYP) 27B1, inactivated by CYP24A1, transported in kidney by Vitamin D binding protein (VDBP, encoded by GC gene) and carries out its activities through its receptor (VDR). No data are available concerning vitamin D genetics and response to anti-TNF drug adalimumab. The aim of this study was to describe the relationship between vitamin D pathway-related gene single nucleotide polymorphisms (SNPs) and adalimumab clinical outcome in a cohort of patients affected by Crohn’s disease. Methods We performed a multi-centre prospective study including patients affected by Crohn’s disease who started adalimumab therapy. SNPs in CYP27B1, CYP24A1, GC and VDR genes were analysed. Clinical outcome was considered as clinical response and remission at 3 months of therapy. Results We enrolled 69 patients. Median age was 40 (IQR 31–56) years, males were 40 (58%). Median basal calprotectin was 396 (IQR 188–851) mg/Kg, and 36 (53.7%) had a positive PCR value. We documented the following associations: CYP27B1 + 2838 CT/TT with perianal disease (p= 0.002), basal calprotectin (p= 0.018) and T3 calprotectin (p= 0.035), figure 1; CYP27B1-1260 GT/TT with perianal disease (p= 0.006), basal calprotectin (p= 0.036) and T3 calprotectin (p= 0.024); VDR ApaI CA/AA with basal calprotectin (p= 0.014) and T3 calprotectin (p= 0.036); VDR BsmI GA/AA with perianal disease (p= 0.036), and GC 1296 TG/GG with basal calprotectin (p= 0.014), figure 2. GC 1296 TG/GG genotype polymorphism (p= 0.044, figure 3) predicted clinical remission at multivariate analysis. Finally, median concentrations adalimumab trough levels at 3 months were 7.4 (IQR 5.5; 11.7) ug/mL. CYP24A1 3999 (p=0.025) and VDR TaqI (p=0.016) SNPs affected these levels. Conclusion This is the first study reporting the association between vitamin D pathway-related genetics and adalimumab treatment in a cohort of patients affected by IBD. Further studies in different and larger cohorts are needed to clarify these aspects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|